医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmatech and InQui Capital Team Up to Offer Development Services to Life Science Startups

2015年06月02日 PM10:06
このエントリーをはてなブックマークに追加


 

HAYWARD, Calif.

Pharmatech Associates and InQui Capital of Hong Kong today announced the Pharmatech Connect program, a collaboration bringing development opportunities to early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide.

Pharmatech Connect is a program created by Pharmatech Associates to provide early to mid-stage life sciences companies with financial resources to enable and accelerate development. The program services include identification and introduction of investors to cover the full range of development costs encompassing expertise in: global regulatory, technical development, manufacturing and compliance requirements, strategic partnering, business development and global healthcare investment services.

“Leveraging our experience along with that of InQui Capital, Pharmatech Connect is intended to bring together resources to boost the development of novel; biologicals, pharmaceuticals and medical devices,” said Warren Baker, Chief Executive Officer, Pharmatech Associates. “The healthcare market is global, and we are working locally and globally with companies to develop better drugs and therapies that result in healthier populations.”

“InQui Capital is pleased to team up with Pharmatech Associates to help life sciences companies realize their business goals and expand into the China market, one of the largest in the world,” said Dr. Juliana Xu, InQui Capital.

About Pharmatech Associates

Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech’s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Product and Process Development, Compliance, Regulatory, and Validation. This interconnected framework of services denotes the Pharmatech EcosystemTM. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area.

About InQui Capital

InQui Capital Ltd. is a Hong Kong-based consulting and investment firm focusing on life science-related sectors. InQui serves as a gateway between China and the West by helping small to mid-size companies find strategic partners both locally and globally. Its founders have extensive experience and knowledge in the global health care market, ranging from fund raising, IPO, cross-border mergers & acquisitions, intellectual property and securities law. InQui assists clients from the inception of their business, grows with them through fund raising, technology transfers, corporate development, and builds them into leaders in their fields.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602005130/en/

CONTACT

SIPR for Pharmatech
Judy Curtis, + 1 650-274-1509
judy@sipr.com
or
Pharmatech
Jerry
Beers, + 1 510-732-0177
jbeers@pharmatechassociates.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結